We are led by a world-class management team of industry leaders who have proven experience in the basic science and clinical development of radiation sensitizers for the treatment of cancer.
Anatoly Dritschilo, MD
CEO & Chairman
Dr. Dritschilo is a co-founder of the Company and has served as Chairman of the Board and Chief Executive Officer since company formation in December 2012. Dr. Dritschilo is a radiation oncologist by training and has held multiple leadership positions in health care. At Georgetown University Medical School in Washington, D.C., he served principally as Department Chair from 1980 to 2018; Chief of Radiation Oncology at MedStar-Georgetown University Hospital from 2005 to 2016; Medical Director of Georgetown University Hospital from 1994 to 1997; and Interim Director of the NCI-funded Lombardi Comprehensive Cancer Center from 2005 to 2007. He has also served on the Boards of Directors of MedStar-Georgetown University Hospital, the National Capital Rehabilitation Hospital and the MedStar Research Institute. His experience with Pharma includes Board of Directors membership of NeoPharm, Inc, and he was a founding director of Oncomed (Neopharm). His 200+ scientific publications and 12 issued patents have earned him election as a Fellow of the National Academy of Inventors. Dr. Dritschilo holds a BS degree in Chemical Engineering from the University of Pennsylvania, his medical degree from the College of Medicine of New Jersey and residency training from the Harvard, Joint Center for Radiation Therapy. His qualifications support his service as CEO and Chairman of the Board of Directors of Shuttle Pharmaceuticals, Inc.
Peter Dritschilo, MBA
President & COO
Mr. Dritschilo has served as President and Chief Operating Officer of Shuttle Pharmaceuticals since 2012, with responsibility for operations and general management of Shuttle Pharmaceuticals, Inc. He manages the company’s human resources, government grants and contracts and general operations. Over the past 25 years, Mr. Dritschilo has held oncology leadership positions in both community and academic healthcare systems Virginia, Maryland, Maine, South Carolina and Massachusetts. In these roles, he led the growth and strategic development of oncology programs, including Radiation Oncology, Medical Oncology, Surgical Oncology, Cancer Research, Genetic Counseling, Stem Cell Transplant and Interventional Oncology. Mr. Dritschilo also has experience with independent cancer centers, where he served as the COO and partner for a free-standing radiation oncology center. Prior to embarking on these leadership roles, Mr. Dritschilo worked as a radiation therapist, delivering radiation treatments to cancer patients. He earned a Master’s degree in Business Administration from The George Washington University in 2003, a Bachelor of Art degree from Georgetown University in 1992, and an Associate’s Degree in Radiation Therapy Technology in 1994.
Mira Jung, PhD
Founder & Scientific Director
Dr. Jung is a co-founder of the Company and has served as our Chief Scientific officer for Biology and as has been a member of our board of directors since we were formed in December 2012. Since 2005, Dr. Jung has served as Professor of Radiation Medicine and Microbiology at Georgetown University Medical School, with over 20 years of experience in molecular radiation biology research. She is an expert in mechanisms of radiation resistance and on the roles of HDAC inhibitors in modifying the radiation response. Dr. Jung’s research has been funded by NIH and the DOD leading to 100 publications and six issued patents, including the first reports of HDAC inhibitor drug classes modifying cancer cell radiation resistance and protecting normal tissues from radiation damage. Dr. Jung holds an MA degree and a PhD in Microbiology and Molecular Virology from the University of Kansas. Dr. Jung provides experience and expertise in the discovery and development of new HDAC inhibitors and their pre-clinical evaluation and is uniquely qualified to serve as an officer and director.
Tyvin Rich, MD
Chief Medical Officer
Dr. Rich serves as the Company’s Chief Medical Officer and is responsible for the clinical development of novel radiation sensitizers. Since 2010, Dr. Rich has served as a Staff Radiation Oncologist at the Hampton University Proton Therapy Institute in Hampton Virginia and Professor Emeritus at University of Virginia Health Sciences Center, Department of Radiation Oncology. From 1995 until 2010, Dr. Rich was a Professor and Chairman of the Department of Therapeutic Radiology and Oncology at the University of Virginia Health Sciences Center. And prior to that, from 1984 through 1995, Dr. Rich was a Professor of Radiotherapy and Director of Clinics in the Department of Radiotherapy of the University of Texas M. D. Anderson Cancer Center. He has served as the protocol chair for RTOG clinical trials that advanced the use of chemoradiation for the treatment of rectal and pancreatic cancers. He is an expert in the applications of infusional 5-Fluorouracil for chemoradiation therapy of gastro-intestinal cancers and has authored more than 200 scientific articles, reviews and book chapters. Dr. Rich received his undergraduate degree at Rutgers University, his medical degree at the University of Virginia, and completed residencies in internal medicine at Georgetown Medical Division and radiation therapy at Massachusetts General, Harvard Medical School. We believe his extensive experience in radiation oncology and clinical trials will enable Ropidoxuridine and Doranidazole clinical development.
Michael Vander Hoek, MHSA
CFO & VP Regulatory
Mr. Vander Hoek serves as the Company's Chief Financial Officer, a position he was appointed to in August 2019, and Vice President, Operations and Regulatory, a position he has held since 2018. Over the past 30, he has held several leadership positions within Georgetown University and MedStar Health, the Georgetown Lombardi Comprehensive Cancer Center's clinical partner and Washington, D.C.'s largest regional health care provider. As Associate Director for Administration from 2007 to 2020, Mr. Vander Hoek managed over 400 faculty scientists, staff and research fellows in the departments of Oncology; Radiation Medicine; Pathology; and Biostatistics, Biomathematics, and Bioinformatics. He also managed a 5-year, $221.9 million institutional commitment to cancer research. Mr. Vander Hoek was Georgetown University’s administrative lead for implementing a $14 million enterprise-wide clinical trial management system in 2017 and was responsible for approval of all cancer clinical trial budgets. Mr. Vander Hoek holds a Master’s in Health Services Administration from The George Washington University, a Bachelor’s in Biology and Psychology from Hope College and completed the Georgetown University Executive Leadership Program in 2018. He served on the Association of American Cancer Institutes’ Finance and Investment Committee during the past decade and the Cancer Center Administrators’ Forum IT Steering Committee. We believe his extensive experience managing large medical and research organizations and publicly held companies will provide valuable insight and assistance as we grow our Company.